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The current protocols for blocking backgroundstaining in immunohistochemistry are basedon conflicting
reports. Background staining is thought to occur as a result of either non-specific antibody (Ab) binding to
endogenous Fc receptors (FcRs) or a combination of ionic and hydrophobic interactions. In this study, cell
and tissue samples were processed according to routine protocols either with or without a blocking step
(goat serum or BSA). Surprisingly, no Abs in samples processed without a blocking step showed any
propensity for non-specificbinding leading tobackgroundstaining, implying that endogenousFcRs donot
retain their ability to bind the Fc portion of Abs after standard fixation. Likewise, we did not find any
non-specific Ab binding ascribable to either ionic or hydrophobic interactions. We determined that
traditionally used protein blocking steps are unnecessary in the immunostaining of routinely fixed cell and
tissue samples.
A
lthough the causes of non-specific background immunostaining may differ, they all equally complicate
the use of immunohistochemistry. Whereas unwanted background staining due to endogenous enzyme
activities or endogenous biotin is no longer a problem in contemporary immunohistochemistry, non-
specific antibody (Ab) bindingleading to unwanted background staining remains subjecttoconsiderable debate.
Among the possible causes of non-specific binding of Abs, the attraction of primary and secondary Abs to
endogenous Fc receptors (FcRs) is thought to be the main source of unwanted staining.
FcRs are structures on the surface of certain cells that bind the Fc region of Abs. Cross linking of Ab bound by
FcRs provides an important link between the cellular and humoral branches of the immune system by inducing
severalresponses,includingphagocytosis,endocytosis,antibody-dependentcytotoxicity,releaseofinflammatory
mediators, and enhancement of antigen presentation
1. The nature of the response depends primarily on the cell
typeonwhichtheseFcRsareexpressed.ThereareseveraltypesofFcR,whichareclassifiedonthebasisofthetype
of immunoglobulins that they recognise
2. FcRs for immunoglobulin G (IgG), the most common class of Ab used
in immunohistochemistry, are designated Fc-gamma receptors (FccRs). Other FcRs are expressed on multiple
cell types and are similar in structure to MHC class I. Being involved in antigen presentation, these receptors can
also bind IgG
3.
It is theorised that FcRs bind the Fc region of Abs not only in vivo but also during immunohistochemical
assays of cell and tissue samples. This concept has been mentioned in all publications regarding immunohisto-
chemistry since itsinception half acentury ago
4–7,but wehave been unableto find the original source of the idea.
It is thought that preincubation of a histological sample with 5–10% normal serum from the species that the
secondary Ab is derived from will prevent non-specific binding of secondary Abs to endogenous FcRs. This
makes little sense for the immunohistochemical staining of human cell and tissue samples, as the vast majority
of secondary Abs used in human immunohistopathology are derived from goats, and goat serum has long been
reported not to bind to FcRs on human cells
8. Preincubation with solutions containing normal goat serum have
also been assumed to prevent background staining that might result from ionic and hydrophobic interactions
5.
Blocking the non-specific background due to FcRs or ionic and hydrophobic interactions is considered an
obligatory step prior to incubation with primary Ab. This can be observed in immunohistochemical protocols in
all contemporary Ab manufacturers’ catalogues (e.g., Dianova, ZytoMed and Jackson ImmunoResearch
Laboratories Inc.), as well as on the popular IHC WORLD homepage and the homepages of the Ab manu-
facturers. All Ab manufacturers offer their own ready-to-use blocking solutions, and their formulations are
trade secrets in many cases.
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cells
8,goatserumremainsthemostpopularblockingagentinhuman
immunohistopathology. Some histochemists prefer FcR blocking
with normal swine or rabbit serum
9, but do not provide any experi-
mental support for their preference. Additionally, more complicated
blocking strategies have been reported, such as employing papain-
digestedfragmentsofunlabeledsecondaryAbenrichedwithFcfrag-
ments of the same IgG
10. In theory, the most rational approach to
prevent the possible non-specific background due to FcR binding
would be the use of F(ab9)2 fragments of Ab instead of the whole
IgG molecule
11, provided that the endogenous FcRs do retain their
ability to bind the Fc portion of IgG Ab after proper fixation.
Other blocking solutions based on bovine serum albumin (BSA),
coldwater fish gelatine, tryptone casein peptone, non-fat dry milk or
casein are thought to prevent non-specific background by blocking
hydrophobic interaction between proteins and ionic or electrostatic
interactions
9, 12, 13.Caseinisthoughttobemoreeffectivethannormal
serum for blocking hydrophobic background staining
7. However,
casein, BSA, and dry milk can all contain bovine IgG
14. Many sec-
ondary Abs, such as anti-bovine Ig Ab, anti-goat Ig Ab, and anti-
sheepIgAb,willreactstronglywithbovineIgG.Therefore,theuseof
BSA, dry milk or casein as a blocking agent may actually increase
background and reduce antibody titer. Somewhat more complicated
methods thought to reduce Ab binding to tissue proteins include
using diluent buffers with low ionic strength, and adding non-ionic
detergents (such as Tween 20 or Triton X) or ethylene glycol to the
diluent
15, 16. Other techniques thought to decrease background
include co-incubation of primary antibodies with reduced glu-
tathione, L-cysteine, iodoacetic acid, Ellman’s reagent and other
thiophilic reagents
17, 18.
It has not been explicitly documented whether the non-specific
bindingofFcfragmentsofAbisequallyproblematicforfrozentissue
sectionsandparaffin-embedded tissuesections.Itisthoughtthatthe
non-specific staining due to the attraction of Fc fragments to FcRs is
more common in frozen sections than in routinely aldehyde-fixed,
paraffin-embedded tissue sections
19, 20. Others have stated that the
increased hydrophobicity of proteins after aldehyde fixation and
paraffin embedding increases the non-specific binding of the Fc
portion of IgG Ab
7, 9. Non-specific staining in paraffin sections has
alsobeenpresumedtooccurbecauseofattractionoftheFcportionof
IgG Ab to basic groups present in collagen fibres
21.
The reports of possible background immunohistochemical stain-
ingduetonon-specificAbbindinginfrozen andparaffin-embedded
tissue sections and in cytological preparations are conflicting, and
most of these reports are outdated and lack clear-cut experimental
support. This prompted us to explore whether commercially
Figure 1 | ImmunohistochemicalstainingofhumantissuesamplesprocessedwithouttheproteinblockingsteppriortoincubationwithprimaryAbs.
Bound primary Abs were detected using DAKO EnVision1 System-HRP (DAKO Corporation, Hamburg, Germany) or AmpliStain
TM HRP conjugate
(SDT GmbH, Baesweiler, Germany) with NovaRed substrate kit. Nuclei counterstained with Ehrlich hematoxylin. (a–c) Immunostaining of human
tissue cryosections after routine formaldehyde fixation (3 min by room temperature). (d–f) Immunostaining of routinely formaldehyde-fixed paraffin-
embeddedhumantissuesections.(a)ImmunolabellingofCD34incapillaryendotheliumofhumankidney.(b)Immunolabellingofcytokeratins8/18/19
inhumanpancreascarcinoma.(c)Immunolocalization ofaSmoothMuscleActininarterialcellwallinhumankidney.(d)ImmunolabellingofCD20in
Blymphocytes inhuman tonsil.(e)Immunolabelling ofGlialFibrillary Acidic Protein inhuman brain tumorastrocytoma. (f)Specificimmunolabelling
ofcollagen IVin blood vessel adventitia in inflammatory bone tissue. Note that collagens inconnective tissue (collagen I) and in bone (collagen I andV )
do not demonstrate any affinity to Fc fragments of either primary or secondary Ab.
www.nature.com/scientificreports
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the immunolabelling of routinely fixed cell and tissue samples.
Results
Immunostaining on two immediately adjacent sections with and
without the blocking step was evaluated by three microscopists in
a researcher-blinded manner. We observed no differences in
immunostainingbetweencellandtissuesamplesthatwereprocessed
either with or without protein blocking. Contrary to the belief that
nonspecific background staining is more common for frozen sec-
tions and cell smears than for paraffin-embedded tissue sections
19,
20, background staining did not appear to be a problem with frozen
tissue sections fixed either with formaldehyde (Fig. 1a–c) or with
acetone. We also observed no difference between preparations with
blood cell smears, cell culture monolayers and cytospins processed
either with or without protein blocking and fixed in methanol (not
shown).
In paraffin sections of formaldehyde-fixed human tissue samples
processed without the protein blocking step (Fig. 1d–f), we did not
observe any background staining that could be ascribed to the
increased hydrophobicity of proteins after aldehyde fixation and
paraffin embedding
7, 9. Contrary to the belief that non-specific stain-
ing might take place in paraffin sections because of attraction of the
Fc portion of IgG Ab to basic groups present in collagen fibres
21,w e
did not observe any nonspecific background immunostaining in
paraffin sections of various collagen-rich tissues, such as media of
blood vessels (Fig. 1c), inflammatory bone tissue (Fig. 1f) or bone
tissue seen in bone marrow preparations (Fig. 2a).
InviewofthefactthatFcRsareexpressedprimarilyonmonocytes,
macrophages, B cells, dendritic cells, neutrophils and platelets
2,w e
paid special attention to cell and tissue samples where these cells are
abundant, specifically bone marrow, spleen, tonsils and blood cell
smears. As demonstrated by CD20 immunolabelling of human ton-
sils(Fig.1d)andwithbonemarrowpreparationsimmunostainedfor
CD20, CD61 and CD68 (Fig. 2), no unwanted background was
observed in tissue samples processed with the omission of protein
blocking prior to incubation with primary Ab. Likewise, no
unwantedbackgroundwasfoundinthecorrespondingnegativecon-
trols with the omission of incubation with primary Abs. Because of
this,weconcludedthatendogenousFcRsdonotretaintheirabilityto
bind the Fc portion of IgG Ab after fixation routinely used in
immunohistochemistry.
After performing immunostaining using fluorophore-conjugated
Abs, wealsofound thatthe omission of the proteinblocking step did
not lead to non-specific background staining in single or multiple
fluorescence immunolabelling with the use of either fluorophore-
conjugated Ab or streptavidin. This is demonstrated with the immu-
nofluorescent triple staining of cytokeratin 5, cytokeratin 10 and
cytokeratin 14 in adeno-squamous carcinoma of the human mam-
mary gland (Fig. 3).
This was a clinically oriented study focused on human patient
tissue samples. However, many researchers perform immunohisto-
chemistry on tissues from experimental animals, particularly rodent
tissues. Because of this, we performed immunostaining also on neo-
natal-rat-cultured cardiomyocytes, mouse and rat tissue samples
(Fig. 4), as well as on tissue samples taken from cow and swine
(not shown), processed either with or without the protein blocking
step. Similar to immunostaining of human cell and tissue samples,
omission of the protein blocking step did not lead to unwanted
background staining in histological samples from experimental
and farmed animals.
Discussion
During the past few decades, improvements in the reagents and
protocols used for immunohistopathology have led to increased
sensitivity of detection systems, widely contributing to the
Figure 2 | Immunodetection of markers of Clusters of Differentiation
(CD)inbonemarrowpreparationsprocessedwithouttheproteinblocking
step prior to incubation with primary Abs. (a) Immunolabelling of CD20
in B lymphocytes. (b) Immunolabelling of CD61 in megakaryocytes and in
thrombocytes. (c) Immunolabelling of CD68 in fibroblastic dendritic cell
and in monocytes. Bound primary Abs were visualized using AmpliStain
TM
HRP conjugate (SDT GmbH, Baesweiler, Germany) with NovaRed
substrate kit. Nuclei counterstained with Ehrlich hematoxylin.
Immunohistochemical staining was performed without protein block prior
to incubation with primary Ab. Note in (a) the absence of unspecific Ab
binding to bone tissue and to hematopoetic cells, in (b) the absence of
unspecificAbbindingtogranulocytesandmonocytesandin(c)theabsence
of unspecific Ab binding to granulocytes and megakaryocytes.
www.nature.com/scientificreports
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current protocols for blocking unwanted background signals are
based on conflicting and outdated reports. The concepts of the
attraction of Fc portions of Ab to FcRs and of non-specific Ab bind-
ing due to hydrophobic interaction between proteins and ionic and
electrostaticinteractionsseemtoreflectdesperateattemptsofimmu-
nohistochemistshalfacenturyagotofindaplausibleexplanationfor
poor immunostaining with home-made Abs that were not always of
the best quality. During this time period, antisera were occasionally
collected and stored in inappropriate ways, and primary Abs were
sometimes applied in supra-optimal concentrations. Non-specific
background immunostaining may have also resulted from other fac-
tors, such as inappropriate immunohistochemical detection meth-
ods, protracted time of chromogen application, improper fixation,
protracted fixation timeand intervalbefore fixation.Maintenance of
the specimen’s morphology during fixation is the most important
prerequisite for good immunostaining
22. If the specimen’s morpho-
logy is poor, one cannot expect a quality result.
This study was performed on cryosections, cell culture mono-
layers, blood cell smears and cytospins fixed for no longer than
15 min in either acetone or alcohol. For paraffin embedding, cell
and tissue samples were fixed in 4% buffered formaldehyde for 18–
48 hrs at room temperature. Evaluation of the possible undesirable
effects of either protracted fixation or the use of stronger fixation
media was beyond the scope of this study because the influence of
fixation strength and duration on the availability and conformation
of antigen epitopes and on specimen morphology is unknown and
often unpredictable. To allow proper evaluation and replication of
our immunohistochemical experiments, Abs in this study were
applied strictly according to manufacturers’ recommendations.
Using these standardised conditions, we did not observe any differ-
ences in immunostaining in any samples processed either with or
without protein blocking. This means that the protein blocking step
traditionally used in immunohistochemistry does not influence the
qualityofimmunostainingandthatomissionoftheproteinblocking
step does not lead to unwanted background staining.
Our data allowed us to conclude that endogenous FcRs do not
retain the ability to bind the Fc portion of IgG Ab after fixation in
formaldehyde,acetoneoralcohol.Likewise,non-specificAbbinding
totissueproteinsduetohydrophobicinteractionbetweenproteinsor
ionic and electrostatic interactions does not take place in routinely
fixed cell and tissue samples. In contrast to the commonly accepted
view, we found that the protein blocking step traditionally used in
immunohistochemistry is unnecessary in the immunostaining of
routinely fixed cell and tissue samples taken both from human
patients and from nonhuman species. Omission of the traditional
proteinblockingstepmaysavesubstantialreagentcostsandprepara-
tion time both in research and immunohistopathology.
Methods
We performed comparative immunostaining procedures with and without the pro-
tein blocking step on frozen and paraffin-embedded tissue sections, as well as on cell
culture monolayersand cytospins. For paraffin embedding, tissue samples were fixed
with 4% formaldehyde in PBS. Four-micrometre-thick paraffin tissue sections were
deparaffinised with xylene and graded ethanol, and antigen retrieval was performed
byheatingthesectionsin10 mMsodiumcitratebuffer,pH 6.0,at95uCfor30 minin
a domestic vegetable steamer
23. Frozen tissue sections, cell monolayers, blood cell
smears and cytospins were immunostained after fixation with 4% formaldehyde,
methanol or acetone. The blocking step prior to incubation with the primary Ab was
performed with either 5–10% normal goat serum or 1% BSA in PBS.
All Abs were applied according to manufacturers’ recommendations. The final
concentration of primary Ab was between 1 and 5 mg/ml PBS. For immunostaining,
we used 45 mouse monoclonal and rabbit polyclonal primary Abs (Table 1). For
bright-field microscopy, bound primary Abs were detected with a EnVision Horse
RadishPeroxidase(HRP)System(DAKOCorporation,Hamburg,Germany)orwith
an AmpliStain
TM HRP conjugate (SDT GmbH, Baesweiler, Germany) according to
the manufacturers’ instructions. HRP labelling was visualised using a NovaRed
substrate kit (Vector Laboratories, Burlingame, CA, USA). For fluorescence micro-
scopy, we used a goat secondary Ab conjugated with Cy3, Alexa Fluor-488, Alexa
Fluor-647orbiotin.Thelatterwasvisualisedusingfluorophore-labelledstreptavidin.
Secondary Abs and other reagents used in this study are listed in Table 2. The final
concentration of secondaryAb wasbetween 5 and 10 mg/ml PBS. Single and multiple
immunofluorescence labelling were performed according to standard protocols
23.
Immunostained sections were examined on a Zeiss Axio Imager Z1 microscope.
Microscopy images were captured using AxioCam digital microscope cameras and
AxioVision image processing (Carl Zeiss Vision, Germany). The images were
acquiredat96DPIandsubmittedwiththefinalrevisionofthemanuscriptat300DPI.
Figure 3 | Immunofluorescent triple staining of cytokeratin 5, cytokeratin 10 and cytokeratin 14 in adeno-squamouse carcinoma of human mammary
gland. Immunolabellingwasperformedwithouttheproteinblockingsteppriortoincubationwithprimary Abs.(a)Immunolocalizationofcytokeratin14
(Alexa 488, green channel). (b) Immunolocalization of cytokeratins 10 (Cy3, red channel). (c) Immunolocalization of cytokeratin 5 (Alexa 647, pink
channel). (d) Composite image. Nuclei are counterstained with DAPI.
www.nature.com/scientificreports
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fromexperimentalanimals. Immunolabellingwasperformedwithoutthe
protein blocking step prior to incubation with primary Abs. Bound
primary Abs were detected using AmpliStain
TM HRP conjugate (SDT
GmbH, Baesweiler, Germany) with NovaRed substrate kit. Nuclei
counterstained with Ehrlich hematoxylin. (a) Immunostaining of desmin
in neonatal-rat-cultured cardiomyocytes. (b) Immunostaining of a
SmoothMuscleActinintherataortacellwall.Notethatcollagensinelastic
laminae do not demonstrate any affinity to Fc fragments of either primary
or secondary Ab. (c) Immunostaining of Ki67 in the mouse spleen. (d)
Immunostaining of Ki67 in the mouse gut.
Table 1 | Primary antibodies used in this study
Antibodies Source Dilution Tissues/Cells*
IgA (alpha), (rabbit Ab) DAKO 1/2000 1, 2, 3
IgG(gamma),(rabbitAb) DAKO 1/1000 1, 2, 3
IgM (my, m), (rabbit Ab) DAKO 1/1000 1, 2, 3
Bcl2 (mouse Ab) DAKO 1/100 2, 4, 5, 6, 7
a Smooth Muscle Actin
(mouse Ab)
DAKO 1/50 4, 5, 6, 7, 8, 9
a Smooth Muscle Actin
(rabbit Ab)
AbCam 1/200 4, 5, 6, 7, 8, 9
ApoE (rabbit Ab) Santa Cruz 1/100 10
CD3 (mouse Ab Novocastra 1/200 2, 23
CD10 (mouse Ab) Novocastra 1/50 5
CD20 (mouse Ab DAKO 1/500 2, 3, 10
CD32 (mouse Ab) AbCam 1/1000 3, 23
CD34 (mouse Ab) Novocastra 1/50 1, 9, 25
CD61 (mouse Ab) Novocastra 1/100 10
CD68 (mouse Ab) DAKO 1/200 2, 3, 10
CD117, c-Kit (rabbit Ab) DAKO 1/100 4, 5
Cytokeratins 5 (rabbit Ab) Medac 1/100 4, 5, 6, 7, 8, 24, 25
Cytokeratin 5/6
(mouse Ab)
DAKO 1/50 4, 5, 6, 7, 8, 24, 25
Cytokeratin 7(mouseAb) DAKO 1/200 4, 5, 6, 7, 8, 24, 25
Cytokeratin 10
(mouse Ab)
DAKO 1/50 4, 5, 6, 7, 13
Cytokeratin 14
(mouse Ab)
Jackson
ImmunoRes
1/500 4, 5, 6, 7, 8, 24, 25
Cytokeratin 18
(mouse Ab)
Sigma 1/50 4, 5, 6, 7, 8, 24
Cytokeratin 8/18
(mouse Ab)
Zytomed 1/50 4, 5, 6, 7, 8, 24, 25
Cytokeratin AE1/AE3
(mouse Ab)
DAKO 1/50 2, 4, 5, 6, 7, 13
Cytokeratins 8/18/19
(mouse Ab)
Immunotech 1/100 4, 5, 6, 7, 8, 25
Collagen IV (mouse Ab) DAKO 1/20 5, 11
Desmin (mouse Ab) DAKO 1/200 12, 14
E-Cadherin (mouse Ab) DAKO 1/50 1, 4, 5
Calcitonin (rabbit Ab) DAKO 15500 15
Calponin (mouse Ab) DAKO 1/50 9, 16, 17
EMA (mouse Ab) DAKO 1/50 1
Estrogen Receptors
(rabbit Ab)
Thermo 1/200 4, 5
GFAP (mouse Ab) DAKO 1/100 18
GFP (rabbit Ab) AbCam 1/500 19
HMB45 (mouse Ab) DAKO 1/50 13
Kappa Light Chains
(rabbit Ab)
DAKO 1/8000 2, 10
Lambda Light Chains
(rabbit Ab)
DAKO 1/8000 2, 10
Ki67 (rabbit Ab) Thermo 1/200 2, 4, 5, 6 , 7, 24
MIB1 (mouse Ab) DAKO 1/20 2, 4, 5, 6 , 7, 24
Myf-4 (mouse Ab) Zytomed 1550 20
nNOS (rabbit Ab) Transduction
Lab.
16, 17, 21, 22
eNOS (rabbit Ab) Transduction
Lab.
9, 16, 17, 21, 22
P53 (mouse Ab) DAKO 1/50 5, 7
p63 (mouse Ab) DAKO 1/200 4, 5, 6, 7
S100 (rabbit Ab) DAKO 1/2000 2, 5, 7, 10
Vimentin (mouse Ab) DAKO 1/200 15
Vimentin (rabbit Ab) AbCam 1/1000 5, 9
*Cell and tissue samples immunostained in this study: Human kidney (1), Human tonsil (2), Human
lymphnodes(3),Humanmammarygland(4), humanbreasttumors(5),Humansalivarygland(6),
Human salivary gland tumors (7), Human lacrimary gland (8), Human aorta (9), Human bone
marrow (10), Human bone tissue (11), Human gastrointestinal tissue (12), Human skin (13),
neonatal-rat-cultured cardiomyocytes (14), Human thyroid gland (15), Human muscle tissue (16),
Rat muscle tissue (17), Human brain astrocytoma (18), Mouse heart, spleen and kidney (19),
Human rabdomyosarcoma (20), Human pancreas (21), Rat pancreas (22), Human blood cell
smears and cytospins (23), Cell cultures of human adenoid cystic carcinoma (24), Cow and pig
mammary gland (25)
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Table 2 | Secondary antibodies and other reagents
Antibodies Source Dilution Label
Goat Normal Serum Jackson ImmunoRes 1/100 w/o
Mouse Normal Serum Jackson ImmunoRes 1/100 w/o
Bovine serum albumin Biomol 1% w/o
Goat anti–mouse IgG Ab Invitrogen 1/200 Alexa Fluor 488
Goat anti–mouse IgG Ab Invitrogen 1/200 Alexa Fluor 555
Goat anti–mouse IgG Ab Invitrogen 1/100 Alexa Fluor 647
Goat anti–rabbit IgG Ab Invitrogen 1/100 Alexa Fluor 647
Biotin-SP-AffiniPure Fab Fragment Goat Anti-Mouse Jackson ImmunoRes 2–10 mg/ml Biotin
Biotin-conjugated anti-mouse IgG3 BD Pharmingen 1/25 Biotin
Streptavidin Jackson ImmunoRes 1/200 Cy3
Anti-mouse EnVision
1 System-HRP DAKO Corporation ready-to-use HRP
Anti-rabbit EnVision
1 System-HRP DAKO Corporation ready-to-use HRP
AmpliStain
TM anti-Mouse 1-Step HRP SDT GmbH, Baesweiler, Germany ready-to-use HRP
AmpliStain
TM anti-Rabbit 1-Step HRP SDT GmbH, Baesweiler, Germany ready-to-use HRP
49,6-diamidino-2-phenylindole(DAPI,nuclearcounterstaining) Sigma 5 mg/ml w/o
VectorH NovaRED
TM Substrate Kit Vector Laboratories, Burlingame, CA, USA ready-to-use w/o
VECTASHIELDH Mounting Medium Vector Laboratories, Burlingame, CA, USA ready-to-use w/o
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